Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AbbVie Inc. reported revenue of $61.16B, up 8.6% year over year. Operating margin was 24.6% and net margin 6.9%, on a free-cash-flow margin of 29.1% with capital expenditure at 2.0% of revenue. Every figure is computed directly from ABBV's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $61.16B | 24.6% | 6.9% |
| FY2024 | $56.33B | 16.2% | 7.6% |
| FY2023 | $54.32B | 23.5% | 9.0% |
| FY2022 | $58.05B | 31.2% | 20.4% |
| FY2021 | $56.20B | 31.9% | 20.5% |
How does ABBV compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · BMY · ABT · AMGN · LIN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.